Combination of NBTXR3 and cisplatin

2017, Pottier A. et al.

Authors

Agnès Pottier1, Sonia Vivet1, Sébastien Paris1, Bo Lu2
1 – Nanobiotix, Paris, France
2 – Thomas Jefferson University, Philadelphia, PA

Summary

Combination of NBTXR3 and cisplatin has been evaluated in vitro and in vivo. No specific toxicity was observed for the cells exposed only to NBTXR3. For the combined treatment, a marked and enhanced cell destruction when compared to the single agent. In vivo, NBTXR3 combined with low dose of cisplatin delayed tumor growth when compared to single agent cisplatin in combination with radiotherapy.

Read Article

Contact

For more information contact our Medical affairs team at medicalaffairs@nanobiotix.com